



IFW
Bot-seq

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Conf. No.:	1668
Strom et al.)		
)	Art Unit:	1653
Serial No.: 10/785,210)		
)	Examiner:	Mayer
Filed: February 24, 2004)		
)	Docket No.:	00588.105030
For: Periodic Antimicrobial Peptides)		

TRANSMITTAL LETTER

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

In response to the Office Action mailed from the United States Patent and Trademark Office October 20, 2004, for which a response with a three-month extension of time is due April 20, 2005, Applicants, through their attorneys and agents, submit the following:

1. Amendment and Response to Non-Final Office Action;
2. Individual Assignment and Inventor's Declaration executed by Robert M. Strom and Philip J. Brondsema;
3. Supplemental Information Disclosure Statement;
4. Form PTO-1449;
5. Cited Reference;
6. Petition for Extension of Time;
7. Replacement of Sequence Listing;
8. Substitute Sequence Listing (paper copy);
9. Substitute Sequence Listing (computer readable copy on diskette);
10. Check for \$450;
11. Certificate of Mailing; and,
12. Postcard.

The Commissioner is authorized to charge all additional fees associated with this response to Deposit Account No. 11-0980.

Respectfully submitted,

By: 
Madeline I. Johnston
Reg. No. 36,174

Date: April 20, 2005

KING & SPALDING LLP
191 Peachtree Street
45th Floor
Atlanta, GA 30303-1763
Tel.: (404) 572-4600



TRANSMITTAL FORM


Certificate of Mailing Under 37 CFR 1.8

I hereby certify that this Response to Non-Final Office Action and all associated documents related thereto and identified in the Transmittal Letter are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the below-identified date.

Deposit Date: April 20, 2005

Docket No.: 00588.105030

Appl. No.: 10/785,210


Name: Brent R. Bellows